Foundation Medicine said on Thursday that the US Food and Drug Administration has approved its FoundationOne CDx test as a companion diagnostic to identify non-small cell lung cancer patients with EGFR exon 19 deletions or exon 21 alterations for treatment with EGFR inhibitors.

Cue Health said on Wednesday that it has received interim order authorization from Health Canada to sell its at-home molecular COVID-19 self-test in that country.

DiaSorin on Wednesday said that its 2021 revenues rose 41 percent year over year.

On March 16, PHASE Scientific’s INDICAID COVID-19 Rapid Antigen At-Home Test get EUA issued by the US FDA.

Joinstar’s COVID-19 Antigen Rapid Test (Colloidal Gold) anterior nasal-self testing device, was awarded the CE certificate issued by EU.

Illumina said on Tuesday that it has received CE-IVD marking for its TruSight Oncology Comprehensive (EU) assay this month.

Burning Rock Biotech said on Tuesday that the National Medical Products Administration of China has approved its nine-gene sequencing assay, LungCure CDx, as a Class III medical device.

The development of new scientific ways to see more deeply into the building blocks of nature on a cellular level has led to the some of the greatest advances in medicine over the last century.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it will invest $97 million to expand its clinical research operations in Richmond, Virginia.

Jilin Province has ordered 12 million antigen detection reagents nationwide in a short period of time, some have been delivered.

Recently, the domestic epidemic situation is severe, and the release of the "Plan" further optimizes the COVID-19 detection strategy to serve the needs of epidemic prevention and control.

Thermo Fisher Scientific has released the Invitrogen SuperScript IV RT-LAMP Master Mix for the fast and sensitive detection of viral pathogens, including SARS-CoV-2, measles, and influenza.

Lucira Health on Thursday reported a huge year-over-year surge in revenues for the fourth quarter of 2021 on ramped-up manufacture and sale of the company's molecular at-home COVID-19 tests.

Cancer detection is a major public health challenge, and the methods currently available to achieve it, for example MRIs and mammograms, are often expensive and invasive.

Oncocyte Corporation reported after the close of market Thursday that its fourth quarter and 2021 revenues rose sevenfold and sixfold, respectively, over their prior-year periods.